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ABSTRACT
Objective: To study the relation between N-terminal pro-brain natriuretic peptide (NT-proBNP) lev-
els, used as a marker of heart failure in clinical practice, blood pressure (BP), and cognitive decline
in the oldest old.
Methods: In 560 participants of the Leiden 85-plus Study, we measured NT-proBNP levels and
BP at age 85 years, at baseline, and global cognitive function (Mini-Mental State Examination
[MMSE]) annually during the follow-up of 5 years.
Results: Subjects in the highest tertile of NT-proBNP levels scored 1.7 points lower on the MMSE
at age 85 years than subjects in the lowest tertile (p 5 0.004), and had a 0.24-point-steeper
decline in MMSE score per year (p 5 0.021). The longitudinal association disappeared after full
adjustment for possible confounders (0.14-point-steeper decline, p 5 0.187). Subjects in the
category “highest tertile of NT-proBNP and the lowest tertile of systolic BP” had a 3.7-point-lower
MMSE score at baseline (p , 0.001) and a 0.49-point-steeper decline in MMSE score per year
(p , 0.001) compared with subjects in the other categories.
Conclusions: In the oldest old, high NT-proBNP levels are associated with lower MMSE scores. The
combination of high NT-proBNP levels and low systolic BP is associated with worst global cognitive
function and the steepest cognitive decline. Possibly, a failing pump function of the heart results in
lower BP and lower brain perfusion with resultant brain dysfunction.Neurology®2014;83:1192–1199
GLOSSARY
BP 5 blood pressure; MMSE 5 Mini-Mental State Examination; NT-proBNP 5 N-terminal pro-brain natriuretic peptide.
Cardiovascular diseases, such as myocardial infarction, generalized atherosclerosis, and stroke
have been associated with increased dementia risk and cognitive decline.1–4 Hypertension,
however, is only a risk factor for dementia when present in middle age, whereas most studies
show that dementia and cognitive decline in the oldest old associate with lower blood pressures.5
In the oldest old, blood pressures decrease over time,6,7 and stronger declines are related to the
presence of dementia and cognitive decline.8,9 One possible explanation for the blood pressure
decline in the oldest old might be the increasing prevalence of (subclinical) congestive heart
failure.10 Despite this dynamic correlation between blood pressure and cardiac function in
relation to cognitive function in old age, previous studies have mainly focused on either the
association of blood pressure or cardiac function with cognitive impairment.
Congestive heart failure has been associated with an increased risk of cognitive impairment.11–13
A frequently used serum marker of heart failure is the N-terminal pro-brain natriuretic peptide
(NT-proBNP), the inactive fragment of the proBNP hormone.14 NT-proBNP has proven to be a
quantitative marker of acute heart failure in clinical practice, with high sensitivity and reasonable
specificity,15 although elevated NT-proBNP levels are not specific for heart failure in the general
population. Several studies have shown that higher NT-proBNP levels associate with lower cog-
nitive function.16,17 However, the relation among NT-proBNP levels, blood pressure, and cog-
nitive function over time in the oldest old has not been studied until now.
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In this study, we examined the associations
among NT-proBNP levels, blood pressure,
and cognitive function in the Leiden 85-plus
Study, a population-based follow-up study in
subjects aged 85 years at baseline. We hypoth-
esized that in the oldest old, high NT-proBNP
levels and low systolic blood pressures associ-
ate with worse cognitive function, and com-
bined high NT-proBNP and low systolic
blood pressure puts the oldest old subjects at
highest risk of cognitive decline.
METHODS Participants. van der Wiel et al.18 described the
participants of the Leiden 85-plus Study: “Between September 1,
1997, and September 1, 1999, a total of 705 inhabitants of the
community of Leiden, the Netherlands, reached the age of 85
years. Among all of these 85-year-old persons, we initiated a
follow up study to investigate determinants of successful aging.
Fourteen inhabitants died before they could be enrolled. The
response rate was 87%; a total of 599 subjects (397 women
and 202 men) participated.” Of the 599 participants in the
cohort, 38 refused to provide a blood sample, and NT-proBNP
measurement failed in one participant, yielding a total number of
560 participants for this study. Participants were visited within
1 month after their 85th birthday at their home for face-to-face
interviews and neuropsychological testing. Each year they were
revisited until age 90 years. Information on the missing follow-up
data has been published before.19
Standard protocol approvals, registrations, and
participant consents. The Medical Ethical Committee of the
Leiden University Medical Centre approved the study, and
informed consent was obtained from all participants.
Plasma levels of NT-proBNP. Nonfasted blood samples were
taken at the first visit early in the morning. Blood samples were
kept frozen at 280°C. Citrated plasma levels of NT-proBNP
were measured in one batch in 2011 using the NT-proBNP
assay, developed by Roche Diagnostics (Mannheim, Germany)
on a Roche Modular E-170 automated immunoanalyzer.
Blood pressure. Blood pressure was measured each year, using a
mercury sphygmomanometer. During each home visit, 2 blood
pressure measurements were taken in seated position, approxi-
mately 90 minutes apart, and after at least 5 minutes of rest
and no vigorous exercise in the preceding 30 minutes. These were
then averaged.
Global cognitive function. At age 85 years and then annually,
global cognitive function was assessed in participants using the
Mini-Mental State Examination (MMSE).20
Other covariates. The level of education of each participant was
defined by less than 7 years of schooling for low education,
whereas high education was defined by more than 6 years of
schooling. The burden of vascular disease at baseline was deter-
mined by the number of cardiovascular and cerebrovascular
pathologies (myocardial infarction, angina pectoris or myocardial
ischemia, claudicatio intermittens, arterial surgery, stroke, and
TIA). Information on the presence of cardiovascular and cerebro-
vascular pathologies was provided by general practitioners or
treating physicians. Information on use of antihypertensive med-
ication was obtained from pharmacist records, or from question-
naires, filled out by the treating physician for institutionalized
participants. Participants were classified as having diabetes
according to previously described criteria.21 Information on
smoking was obtained from questionnaires. Body mass index
was calculated by dividing the weight in kilograms by the square
of length in meters (kg/m2). Creatine clearance was estimated
with the Cockroft-Gault formula. Prevalence of atrial
fibrillation was determined by automated Minnesota Coding
(Minnesota Code 8-3-1) of ECGs, which were recorded on a
Siemens Sicard 440 (Erlangen, Germany), and were transmitted
to the ECG Core Laboratory in Glasgow Royal Infirmary.
Statistical analyses. Characteristics of the study participants are
reported as means (SDs) for continuous variables and numbers
(percentages) for categorical variables in tertiles of NT-proBNP
levels.
The associations of both NT-proBNP levels and systolic
blood pressure with MMSE score at baseline and during
follow-up were analyzed using linear mixed models. Linear mixed
models use all available data during follow-up and account for
repeated measurements, thereby handling missing data more
appropriately than traditional models.22 In the primary analyses,
categorical NT-proBNP levels and systolic blood pressure were
the independent variable, whereby NT-proBNP levels and sys-
tolic blood pressure were divided in tertiles. For continuous anal-
yses, log-transformed NT-proBNP levels were used. In a
multivariate model, all analyses were corrected for level of educa-
tion, use of antihypertensives, smoking status, prevalence of dia-
betes, body mass index, renal function, prevalence of atrial
fibrillation, and finally, the number of cardiovascular and cere-
brovascular pathologies at baseline. In a final analysis, a new var-
iable consisting of 4 categories, using combinations of the lowest
and highest tertile of NT-proBNP levels and the lowest and high-
est tertile of systolic blood pressure, was used as an independent
variable with MMSE scores as the outcome variable. All calcula-
tions were performed using SPSS software (version 20.0.1; SPSS
Inc., Chicago, IL).
RESULTS Baseline analyses. Table 1 shows baseline
characteristics of all 560 study participants in tertiles
of NT-proBNP levels. Compared with subjects in the
lowest tertile, subjects in the highest tertile of NT-
proBNP had a lower educational level, lower systolic
and diastolic blood pressures, lower body mass index,
and lower renal function. Furthermore, they were
more likely to use antihypertensives, to have a
history of smoking, and they had a higher
prevalence of cardiovascular pathologies and atrial
fibrillation.
NT-proBNP levels, systolic blood pressure, and MMSE
scores from age 85 to 90 years. Figure 1A graphically
shows the association between NT-proBNP levels and
MMSE scores for participants aged 85 to 90 years. At
age 85 years, subjects in the highest tertile of NT-
proBNP had a 1.7-point-lower MMSE score than
subjects in the lowest tertile (p 5 0.004). Moreover,
during the 5-year follow-up, subjects in the highest
tertile of NT-proBNP had a 0.24-point-steeper
decline in MMSE score per year compared with
subjects in the lowest tertile (p 5 0.021). Table 2
shows that after additional adjustment for smoking,
prevalence of diabetes mellitus and atrial fibrillation,
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use of antihypertensives, body mass index, and renal
function, subjects in the highest tertile of NT-
proBNP still had a 1.7-point-lower MMSE score at
baseline than subjects in the lowest tertile, but not a
significant steeper decline in MMSE score per year
(0.16-point-steeper decline). Further adjustment for
the number of cardiovascular pathologies at baseline
slightly decreased the baseline association between
NT-proBNP levels and MMSE score. There was
also an association between systolic blood pressure
and MMSE score (figure 1B). Subjects in the lowest
tertile of systolic blood pressure had a 2.8-point-lower
MMSE score at age 85 years than subjects in the
highest tertile (p , 0.001), and they also had a
0.39-point-steeper decline in MMSE score per year
(p , 0.001). Table 2 shows that additional
adjustment in the fully adjusted model did not
materially change the associations.
When analyzing these associations with NT-proBNP
levels and systolic blood pressure as continuous variables
in themodel, similar associations were found. In analyses
adjusted for sex and level of education, higher
NT-proBNP levels were associated with both lower
MMSE scores at baseline (20.57 points MMSE per
1 increase in ln NT-proBNP, p 5 0.007) and with
steeper annual declines in MMSE score from age 85
to 90 years (20.084 points MMSE per year per
1 increase in ln NT-proBNP, p 5 0.012). However,
additional adjustment in a fully adjusted model showed
a diminished effect size and no significant association
(baseline: 20.36 points, p 5 0.131; longitudinal:
20.056 points/y, p 5 0.092). Higher systolic blood
pressures associated strongly with higher MMSE scores
at baseline and with lower annual declines in MMSE
score, also in fully adjusted models (all p , 0.001).
NT-proBNP levels and systolic blood pressures combined.
Finally, to test for the combined effect of NT-
proBNP levels and systolic blood pressure on
MMSE scores, a new variable was created,
including combinations of the lowest and highest
tertiles of NT-proBNP levels and systolic blood
pressure. Table 3 shows the baseline characteristics
of the subjects in the 4 different categories. Figure 2
shows that subjects in the category “high
NT-proBNP and low systolic blood pressure” had
the lowest MMSE score at baseline and had the
steepest decline in MMSE score from age 85 to











n (%) n (%) n (%) p Value
Male 62 (33) 54 (29) 71 (38) 0.176a
Low educationb 115 (62) 112 (60) 134 (72) 0.030a
Use of antihypertensives 66 (36) 87 (45) 96 (51) 0.007a
Current smoking 30 (16) 24 (13) 35 (19) 0.307a
Former smoking 90 (49) 76 (42) 99 (54) 0.048a
Prevalence of DM type II 30 (16) 27 (14) 35 (19) 0.531a
Prevalence of cardiovascular
pathologies
49 (27) 65 (36) 111 (62) ,0.001a
Prevalence of atrial fibrillation 3 (2) 4 (2) 49 (27) ,0.001a
Mean (SD) Mean (SD) Mean (SD)
Systolic blood pressure, mm Hg 156.8 (17.6) 155.9 (18.1) 152.9 (20.0) 0.045c
Diastolic blood pressure, mm Hg 79.0 (9.0) 77.2 (9.4) 74.1 (9.6) ,0.001c
Mean arterial pressure, mm Hg 104.9 (10.5) 103.4 (11.0) 100.4 (11.4) ,0.001c
Pulse pressure, mm Hg 77.8 (14.3) 78.7 (14.6) 78.8 (17.1) 0.553c
Body mass index, kg/m2 28.1 (4.2) 27.4 (4.9) 26.1 (4.0) ,0.001c
Glomerular filtration rate, mL/min 48.7 (11.0) 46.2 (10.6) 40.7 (11.5) ,0.001c
Abbreviations: DM 5 diabetes mellitus; NT-proBNP 5 N-terminal pro-brain natriuretic peptide.
Range of values per tertile: lowest NT-proBNP 5 20.8–200.9 pg/mL; medium NT-proBNP 5 202.7–549.3 pg/mL; highest
NT-proBNP 5 552.9–28,362.7 pg/mL.
aStatistical significance of the difference in number of subjects per tertile, using x2 testing.
b Level of education was dichotomized by 6 years of schooling.
c Statistical significance of the trend over the tertiles, using linear regression analysis.
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90 years. Compared with the other 3 categories,
subjects in the category “high NT-proBNP and low
systolic blood pressure” had a 3.7-point-lower MMSE
score at age 85 years (95% confidence interval 2.1–
5.3, p , 0.001), and a 0.49-point-steeper decline in
MMSE score per year from age 85 to 90 years (95%
confidence interval 0.24–0.75, p , 0.001). In the
fully adjusted model, these associations remained,
although attenuated (baseline: 23.0 points, p 5
0.001; longitudinal: 20.32 points/y, p 5 0.014)
(table e-1 on the Neurology® Web site at
Neurology.org). When restricting the analyses to a
subset of subjects who did not use antihypertensives
at baseline, similar associations were found (table e-2).
When using diastolic blood pressure, mean arterial
pressure, and pulse pressure in the models, similar
associations were found at baseline (all p # 0.001)
and during follow-up for pulse pressure (p , 0.001),
but not for diastolic blood pressure (p 5 0.580) and
mean arterial pressure (p 5 0.089) (figure e-1).
Formal testing for interaction between NT-proBNP
levels and systolic blood pressure in relation toMMSE
score, both in cross-sectional and longitudinal
analyses, showed no interaction in fully adjusted
models (all p . 0.100).
DISCUSSION The main finding of our study is that
higher NT-proBNP levels are associated with worse
global cognitive function at baseline in the oldest
old. Moreover, lower systolic blood pressures were
associated with worse global cognitive function at
baseline and with steeper cognitive decline during
follow-up. When combining NT-proBNP levels
and systolic blood pressures in a new variable,
subjects with both the highest NT-proBNP levels
and lowest systolic blood pressures had the worst
global cognitive function and the steepest cognitive
decline compared with all other subjects.
Our finding of higher NT-proBNP levels associat-
ing with worse cognitive function is in accordance
with previous studies. Both in the Rancho Bernardo
Study and a recently published study of elderly
patients with type 2 diabetes, subjects with high
NT-proBNP levels had worse cognitive function
compared to subjects with low NT-proBNP
levels.16,17 However, these studies reported only on
cross-sectional associations. In the Hoorn Study,
higher NT-proBNP levels at baseline were associated
with worse cognitive function measured after 5 to 8
years.23 There was no information on cognitive func-
tion at baseline, and therefore conclusions on cogni-
tive decline could not be drawn from these results. In
the only study reporting on longitudinal associations,
high NT-proBNP levels were associated with both
steeper declines in MMSE score, measured at baseline
and after 5 years of follow-up, and with an increased
risk of dementia.24 Information on blood pressure was
not reported.
NT-proBNP has emerged as an important bio-
marker of cardiac function and is frequently used in
clinical practice for the evaluation of congestive heart
failure.25 It is the biologically inactive N-terminal
fragment of the prohormone proBNP,26 which is
secreted predominantly by cardiac myocytes of the
ventricles in response to stretching and distension of
the cardiac wall and has a natriuretic and diuretic
effect.27,28 This might explain the observed associa-
tion between high NT-proBNP levels and lower
blood pressures in our study. However, this contra-
dicts with results from previous studies, in which high
NT-proBNP levels were associated with higher blood
pressures, albeit in younger populations.29,30 An
explanation for these opposing results might be that
Figure 1 MMSE score from age 85 to 90 years dependent on tertiles of
NT-proBNP and tertiles of systolic blood pressure
NT-proBNP (A) and systolic blood pressure (B) were divided in equal tertiles. Data points repre-
sent estimates, calculated using linear mixed models, with adjustment for sex and level of edu-
cation. Range of values per tertile: lowNT-proBNP520.8–200.9 pg/mL;mediumNT-proBNP5
202.7–549.3 pg/mL; highNT-proBNP5552.9–28,362.7 pg/mL; low systolic bloodpressure5
110.0–146.5 mm Hg; medium systolic blood pressure 5 147.0–161.5 mm Hg; high systolic
blood pressure 5 162.0–215.0 mm Hg. BP 5 blood pressure; MMSE 5 Mini-Mental State
Examination; NT-proBNP 5 N-terminal pro-brain natriuretic peptide.
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initially, as a consequence of hypertension, higher
filling pressures of the ventricles result in an increased
release of NT-proBNP. However, with longer-
standing hypertension, ventricular enlargement and
dysfunction may develop, leading to heart failure with
lower cardiac output, subsequently resulting in lower
blood pressures.
The use of NT-proBNP levels in the elderly for the
evaluation of cardiac disease is under current debate,
because cutoff values in prediction models show an
age-dependent effect. In our study, subjects in the high-
est tertile of NT-proBNP had levels .550 pg/mL.
When comparing these values to suggested cutoff val-
ues from studies on the use of NT-proBNP levels for
cardiovascular risk prediction in elderly subjects, they
are in the high range. In a study in subjects with a mean
age of 77 years, a cutoff value of 450 pg/mL was used in
the prediction of cardiovascular death.31 Another study
calculated ideal cutoff points in the prediction of
cardiac dysfunction in subjects aged 80 years and
older in different strata of identified confounders.32
Generally, a cutoff value of 400 pg/mL was found. This
however does not necessarily mean that all subjects in
the highest tertile have a severe cardiovascular status.
Because low NT-proBNP levels reliably exclude
heart failure and high NT-proBNP levels are related
to heart failure, our results may suggest that heart fail-
ure associates with worse cognitive function and cog-
nitive decline in the oldest old. The relation between
cognitive function and heart failure, irrespective of
NT-proBNP levels, has been reviewed before.33,34
The authors conclude that there is a strong cross-
sectional association between heart failure and cogni-
tive impairment, but that very few longitudinal data
are available. Possible pathophysiologic mechanisms
explaining the association between heart failure and
cognitive impairment may be found in direct and
indirect pathways. An indirect pathway may be the
presence of common risk factors that associate with
both heart failure and cognitive impairment. Hyper-
tension at midlife for instance is a risk factor for late-
life cognitive impairment,5 but is also a well-known
Table 2 MMSE score at age 85 years and change in MMSE score from age 85 to 90 years dependent on tertiles of NT-proBNP and tertiles of
systolic blood pressure
Tertiles of the determinant
p ValueLowest Medium Highest
NT-proBNP
Cross-sectional (MMSE at age 85)
Model 1 25.7 (24.9–26.6) 24.6 (23.7–25.4) 24.0 (23.1–24.9) 0.004
Model 2 26.1 (24.7–27.4) 25.1 (23.8–26.4) 24.4 (23.3–25.6) 0.009
Model 3 26.1 (24.7–27.5) 25.2 (23.8–26.5) 24.8 (23.6–26.0) 0.041
Longitudinal (annual change in MMSE)
Model 1 20.74 (20.85 to 20.63) 20.65 (20.76 to 20.53) 20.98 (21.11 to 20.84) 0.021
Model 2 20.72 (20.83 to 20.62) 20.65 (20.76 to 20.54) 20.88 (21.01 to 20.74) 0.142
Model 3 20.73 (20.84 to 20.62) 20.67 (20.78 to 20.56) 20.87 (21.01 to 20.73) 0.187
Systolic blood pressure
Cross-sectional (MMSE at age 85)
Model 1 23.1 (22.3–24.0) 25.3 (24.5–26.2) 25.9 (25.1–26.7) ,0.001
Model 2 23.7 (22.6–24.8) 25.4 (24.3–26.4) 25.8 (24.8–26.9) ,0.001
Model 3 24.0 (22.9–25.1) 25.6 (24.5–26.6) 26.0 (24.9–27.1) 0.001
Longitudinal (annual change in MMSE)
Model 1 20.96 (21.08 to 20.83) 20.81 (20.92 to 20.69) 20.57 (20.68 to 20.46) ,0.001
Model 2 20.91 (21.03 to 20.78) 20.79 (20.91 to 20.68) 20.56 (20.66 to 20.45) ,0.001
Model 3 20.92 (21.05 to 20.79) 20.81 (20.92 to 20.69) 20.56 (20.67 to 20.45) ,0.001
Abbreviations: MMSE 5 Mini-Mental State Examination; NT-proBNP 5 N-terminal pro-brain natriuretic peptide.
Data are mean (95% confidence interval). NT-proBNP levels and systolic blood pressure were divided in equal tertiles. Estimates are presented with their
95% confidence intervals, calculated using linear mixed models. In model 1, analyses were corrected for sex and education. In model 2, analyses were
corrected for sex, education, use of antihypertensive medication, smoking, prevalence of diabetes mellitus type II, prevalence of atrial fibrillation, body
mass index, and glomerular infiltration rate. In model 3, analyses were corrected for all variables in model 2, and for the number of cardiovascular
pathologies at baseline. The p value represents the p for trend over the tertiles in the cross-sectional analyses and the p for trend over the “tertiles 3 time
variable” interaction in the longitudinal analyses. Number of subjects per tertile NT-proBNP: lowest, n 5 186; medium, n 5 187; highest, n 5 187. Number
of subjects per tertile systolic blood pressure: lowest, n 5 186; medium, n 5 181; highest, n 5 193.
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risk factor for heart failure up to old age.35 Similar
common risk factors are a history of smoking and prev-
alence of atherosclerotic disease.36–38 Specifically, the
prevalence of atherosclerotic disease may explain the
found associations for a substantial part, because
correction for this variable in the multivariate model
diminished the cross-sectional and longitudinal associ-
ation between NT-proBNP levels and MMSE scores.
However, these indirect pathways may not explain all
of the observed associations between NT-proBNP lev-
els and cognitive function in our study. Another likely
pathophysiologic explanation might be found in the
direct effect of heart failure on cerebral perfusion.
Heart failure is characterized by a decreased cardiac
pump function, with resultant lower cardiac output.
This eventually may result in cerebral hypoperfusion
with concomitant decreased cerebral function. In an
older population of patients with heart failure, ejection
fractions below 30%were indeed associated with worse
memory function.13 In further support of this possible
pathophysiologic mechanism, we showed in a recently
performed meta-analysis that both Alzheimer disease
and vascular dementia are associated with decreased
cerebral blood flow velocities.39
The worst global cognitive function and strongest
cognitive decline were observed in subjects who had
both high NT-proBNP levels and lower systolic
blood pressures, as opposed to all other subjects. This
suggests that specifically the combination of the 2 is
detrimental. A possible explanation for this finding
might be that high NT-proBNP levels reflect a differ-
ent pathomechanism in subjects with lower than in
subjects with higher blood pressures. In subjects with
Figure 2 MMSE score from age 85 to 90 years dependent on categories of
tertiles of NT-proBNP and tertiles of systolic blood pressure
Categories of NT-proBNP and systolic blood pressure were created by making tertiles, and
combining the highest and the lowest tertile of each parameter. Data points represent esti-
mates, calculated using linear mixed models, with adjustment for sex and level of education.
MMSE5Mini-Mental State Examination; NT-proBNP5N-terminal pro-brain natriuretic pep-
tide; SBP 5 systolic blood pressure.














p Valuen (%) n (%) n (%) n (%)
Male 17 (30) 22 (33) 22 (39) 26 (35) 0.800a
Low educationb 32 (57) 42 (64) 38 (67) 57 (77) 0.105a
Use of antihypertensives 19 (33) 27 (41) 25 (44) 38 (51) 0.250a
Current smoking 6 (11) 11 (17) 11 (19) 11 (15) 0.614a
Former smoking 25 (44) 32 (49) 30 (54) 38 (52) 0.726a
Prevalence of DM II 10 (18) 7 (11) 8 (14) 17 (23) 0.258a
Prevalence of CV pathologies 14 (25) 20 (31) 31 (56) 49 (68) ,0.001a
Prevalence of atrial fibrillation 1 (2) 2 (3) 14 (25) 19 (26) ,0.001a
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Body mass index, kg/m2 28.3 (5.2) 28.2 (4.1) 25.9 (4.1) 26.2 (4.3) 0.002c
Glomerular filtration rate, mL/min 49.8 (12.8) 47.9 (10.7) 41.4 (13.4) 41.4 (11.1) ,0.001c
Abbreviations: CV 5 cardiovascular; DM 5 diabetes mellitus; NT-proBNP5 N-terminal pro-brain natriuretic peptide; SBP 5
systolic blood pressure.
Categories of NT-proBNP levels (BNP) and SBP were created by making combinations of the lowest and highest tertile of
both parameters.
aStatistical significance of the difference in number of subjects per category, using x2 testing.
b Level of education was dichotomized by 6 years of schooling.
c Statistical significance of the difference in mean values between the categories, using analysis of variance.
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lower blood pressures, high NT-proBNP levels may
be the result of longer existing heart failure, which re-
sults in cardiac dysfunction, lower cardiac output, and
lower blood pressures. This then eventually may
result in cerebral hypoperfusion. In subjects with
higher blood pressure, high NT-proBNP levels may
be the result of cardiac stress caused by hypertension,
which does not necessarily have a direct negative
impact on cerebral function. This reasoning corre-
sponds with previous findings, in which lower dia-
stolic blood pressure in old age was shown to
associate with increased mortality risk.40 In the Lei-
den 85-plus Study, we previously showed that in the
oldest old, declines in blood pressure during follow-
up associate with increased mortality risk.6,41
A limitation of our study is that information on
cardiac output and cerebral perfusion is not available.
Echocardiography was only performed in a conve-
nience sample of 90 year olds, and unfortunately
not at baseline. With additional information of these
2 parameters, the possible pathophysiologic mecha-
nisms could have been further elucidated. Moreover,
the effect of unmeasured confounding, such as
unmeasured cardiovascular risk factors, cannot be
ruled out. Given that information on blood pressure
measurements before age 85 years was not available, it
was not possible to evaluate the influence of blood
pressure trajectories on our results. A final limitation
is that the MMSE only gives a broad estimate of cog-
nitive function and, although used often in clinical
practice for the assessment of global cognitive func-
tion, does not cover all cognitive domains.
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